Egrifta (Tesamorelin) International Purchase Legalities, Discounts, and Access Options

What Is Egrifta and Why Does Its Legal Status Matter Internationally?

Tesamorelin is a synthetic analogue of growth-hormone-releasing hormone (GHRH). The FDA approved Egrifta in November 2010 specifically for reducing excess abdominal fat in HIV-infected adults with lipodystrophy, based on two Phase 3 trials (LIPO-010 and LIPO-011, combined N=816) that demonstrated a mean trunk-fat reduction of 15.2% versus 5.0% placebo at 26 weeks (P<0.0001) [1]. A reformulated version, EGRIFTA SV (2 mg/vial), received FDA approval in 2019 [2].

Because tesamorelin is a prescription biologic indicated for a narrow population, its regulatory standing differs from country to country. That gap creates confusion for patients who want to cut costs by sourcing it abroad.

FDA Approval Scope

The FDA label restricts Egrifta to HIV-associated lipodystrophy. Off-label use for general body-composition improvement or age-related GH decline is not FDA-sanctioned [2]. This matters for international purchase discussions because any importation must satisfy the original approved indication to have any plausible regulatory defense.

How Other Regulatory Agencies Classify Tesamorelin

Health Canada approved tesamorelin (also branded Egrifta) for the same HIV-lipodystrophy indication. The European Medicines Agency has not granted a full marketing authorization for tesamorelin as of 2026; a positive opinion was withdrawn in 2011 after the benefit-risk assessment did not satisfy EMA standards [3]. That means sourcing from EU-based online pharmacies does not guarantee an EMA-approved product, and may mean the product has no regulatory oversight at all in its country of origin.

Is It Legal to Buy Egrifta From a Foreign Pharmacy?

Purchasing Egrifta from an international pharmacy and importing it into the United States is, in most circumstances, illegal under federal law. The FDA's personal-importation policy does allow limited enforcement discretion for individuals who import a 90-day supply of an unapproved drug for a serious condition when no comparable U.S.-approved treatment exists. Egrifta does not meet that exception because an FDA-approved version is commercially available domestically [4].

The Governing Federal Statutes

Under the Federal Food, Drug, and Cosmetic Act (21 U.S.C. §331), introducing an unapproved new drug into interstate commerce is prohibited [5]. Customs and Border Protection may seize shipments; repeated violations or large quantities can result in criminal referral. The FDA's 2023 Import Alert 66-41 specifically identifies unapproved prescription drugs from foreign sources as subject to detention without examination [6].

The Canadian Pharmacy Question

Canada maintains a licensed pharmacy network (e.g., pharmacies accredited by the Canadian International Pharmacy Association), and Egrifta is Health Canada-approved. However, the drug is still dispensed only by prescription under Canadian law. A U.S. Patient importing from Canada without FDA authorization is violating U.S. Law regardless of the Canadian pharmacy's legitimacy. The FDA issued guidance in 2020 reiterating that personal importation from Canada does not have blanket authorization [7].

Gray-Market and Counterfeit Risk

Research-chemical websites sometimes sell "tesamorelin acetate" as a research peptide. These products are not pharmaceutical grade, are not manufactured under FDA Current Good Manufacturing Practice (cGMP) standards, and have no verified potency or sterility. A 2021 analysis published in JAMA Internal Medicine found that 40% of peptides purchased from unregulated online sources failed identity or purity testing [8]. That figure should give any prospective buyer pause.

How to Get Egrifta Cheaper Through Legitimate U.S. Channels

Theratechnologies Patient-Support Program

Theratechnologies operates a dedicated access program for EGRIFTA SV. Patients who meet income and insurance criteria may qualify for free or reduced-cost drug through this program. The manufacturer's support line (1-877-411-EGRI) connects patients with case managers who handle prior-authorization appeals, specialty-pharmacy coordination, and co-pay assistance enrollment. Specific income thresholds change annually; contact the program directly for 2026 parameters.

Specialty-Pharmacy Copay Cards

Patients with commercial insurance (not Medicare or Medicaid) can access copay-assistance cards that cap monthly out-of-pocket costs. Historically, Theratechnologies has offered cards that reduce eligible patients' cost to as low as $0/month for the first year, subject to program caps. These cards do not stack with federal health-benefit programs under Anti-Kickback Statute provisions [9].

Prior Authorization and Appeals

Most payers require documentation of: confirmed HIV diagnosis, measured lipodystrophy (typically visceral adipose tissue assessed by CT or DEXA), failure of diet and exercise interventions, and specialist attestation. The HIV Medicine Association publishes guidance on lipodystrophy management that can support PA letters [10]. A 2022 review in Open Forum Infectious Diseases found that PA denial rates for tesamorelin exceeded 35% on first submission, but appeal success rates exceeded 60% when specialist documentation was included [11].

340B Program Eligibility

HIV clinics that qualify as 340B covered entities under the Health Resources and Services Administration program can purchase Egrifta at the 340B ceiling price, which is substantially below wholesale acquisition cost. Patients treated at Ryan White HIV/AIDS Program-funded clinics may access tesamorelin at no cost through this mechanism [12]. The HRSA 340B database lists qualifying entities at hrsa.gov.

Compounded Tesamorelin: A Legal U.S. Alternative?

Compounded tesamorelin sits in a nuanced regulatory space. The FDA does not list tesamorelin on its 503B bulk-drug substances list as of early 2026, which means large-scale outsourcing facilities (503B compounders) cannot produce it for office stock. However, state-licensed 503A compounding pharmacies can prepare tesamorelin for an individual patient with a valid prescription when a specific medical need exists that the commercial product cannot meet (e.g., allergy to an excipient, need for a different concentration) [13].

What 503A Compounding Allows

A 503A pharmacy can compound tesamorelin on a patient-specific basis using USP-grade active pharmaceutical ingredient (API). The compound must not be essentially a copy of the commercially available product under 21 U.S.C. §503A(b)(1)(D). Because EGRIFTA SV is commercially available, "essentially a copy" arguments may apply, making the legal ground less stable than with drugs that have no approved equivalent [13].

Quality and Potency Considerations

Compounded peptides vary in purity. The FDA's 2021 compliance policy guidance on compounded drug products notes that compounders must demonstrate API source compliance and finished-product testing [14]. Patients considering compounded tesamorelin should request a Certificate of Analysis (CoA) from the compounding pharmacy showing potency, sterility, endotoxin levels, and identity confirmation by HPLC.

Cost Comparison

Compounded tesamorelin through a 503A pharmacy typically runs $300, $800 per month depending on dose and pharmacy, compared with $6,000, $7,500 WAC for branded EGRIFTA SV. The cost difference is significant, but the regulatory and quality caveats above are real. Any prescriber recommending compounded tesamorelin should document the clinical rationale for deviation from the branded product.

Insurance Coverage: What Payers Require in 2026

Coverage for Egrifta remains highly payer-specific. Medicare Part B covers injectable biologics administered under physician supervision; Medicare Part D covers self-administered injectables. Tesamorelin is self-injected subcutaneously once daily, placing it under Part D in most scenarios [2].

Medicare Part D

Medicare Part D plans categorize specialty biologics on Tier 5, with cost-sharing that can reach 25 to 33% of the drug cost after the out-of-pocket threshold. The Inflation Reduction Act's $2,000 annual Part D out-of-pocket cap (effective 2025) provides some relief, though monthly costs can still reach $500+ before the cap is met [15]. Manufacturer copay cards cannot be used with Medicare Part D.

Medicaid

Medicaid coverage varies by state. Federal law requires Medicaid programs to cover all FDA-approved drugs from manufacturers who have signed a Medicaid Drug Rebate Agreement. Theratechnologies participates in the rebate program, so Egrifta should be covered by most state Medicaid plans for on-label use, though prior authorization is standard [16].

Private Insurance

The HIV Medicine Association's 2023 clinical practice guidelines state: "Tesamorelin 2 mg subcutaneous daily is recommended for HIV-associated lipodystrophy in adults with excess visceral adiposity confirmed by imaging." [10] Including this guideline language in PA documentation strengthens the coverage case.

HSA and FSA Eligibility for Egrifta

Egrifta is eligible for payment through a Health Savings Account (HSA) or Flexible Spending Account (FSA) when it is prescribed for a qualifying medical condition. The IRS defines qualified medical expenses under Section 213(d) of the Internal Revenue Code as those for the "diagnosis, cure, mitigation, treatment, or prevention of disease." [17]

A prescription for tesamorelin written for HIV-associated lipodystrophy meets this definition. Off-label use for body composition in non-HIV patients would also qualify under Section 213(d) as long as a licensed physician prescribed it for treatment of a diagnosed medical condition. The IRS has not issued specific guidance excluding tesamorelin.

Practical Steps for HSA/FSA Use

Patients should obtain an itemized receipt from their specialty pharmacy showing the drug name, NDC, prescribing physician, and date of service. Some HSA/FSA administrators require a Letter of Medical Necessity (LMN) for specialty injectables; ask your prescriber to provide one proactively. FSA funds are use-it-or-lose-it annually (with a 2.5-month grace period or $640 rollover in 2026), so timing the prescription fill matters [17].

Clinical Efficacy Data Supporting Continued Use

Understanding why tesamorelin commands such a high price requires understanding its clinical evidence base. The Phase 3 LIPO-010 trial (N=412) published in the New England Journal of Medicine demonstrated that tesamorelin 2 mg/day reduced visceral adipose tissue by a mean of 18% (measured by CT scan) versus 2% with placebo at 26 weeks (P<0.0001), with sustained benefit at 52 weeks in the extension cohort [18]. A secondary outcome showed improvement in triglycerides (mean reduction of 50 mg/dL versus placebo, P<0.001) [18].

A 2012 meta-analysis in the Journal of Clinical Endocrinology and Metabolism (4 trials, N=1,299) confirmed the visceral-fat reduction and noted that IGF-1 levels normalized in 40% of treated patients without exceeding age-adjusted upper limits of normal [19]. This IGF-1 safety profile distinguishes tesamorelin from exogenous GH, which carries a higher risk of glucose intolerance [20].

The SELECT trial data from 2023 demonstrated that GLP-1 agonists like semaglutide produce significant cardiovascular benefit in non-diabetic patients, which has spurred comparative interest in peptide-based metabolic therapies generally [21]. Tesamorelin's cardiovascular data are more limited: a substudy of LIPO-010 found no significant change in carotid intima-media thickness at 52 weeks, suggesting neutral vascular impact in this population [18].

Risks of International Purchase: A Clinical Summary

Bypassing the U.S. Supply chain for Egrifta exposes patients to four distinct risks.

Regulatory risk. Personal importation without FDA authorization violates 21 U.S.C. §331. Packages can be seized; patients may face legal consequences [5].

Product-quality risk. Unregulated peptide suppliers do not follow cGMP. Contaminated or misdosed product can cause serious harm. The FDA's MedWatch database contains adverse-event reports linked to compounded and counterfeit growth-hormone peptides [14].

Therapeutic risk. Subpotent product will not achieve the visceral-fat reduction documented in the Phase 3 trials. Patients may discontinue prematurely, mistakenly concluding the drug does not work.

Financial risk. Online fraud targeting patients seeking cheaper specialty biologics is documented. The National Association of Boards of Pharmacy's 2024 report found that 96% of online pharmacies reviewed operated outside U.S. Law or pharmacy standards [22].

Practical Decision Framework for Patients and Prescribers

Patients seeking tesamorelin in 2026 should work through these steps in order:

1. Confirm the diagnosis meets the FDA-approved indication (HIV-associated lipodystrophy with CT-confirmed visceral fat excess).
2. Contact the Theratechnologies patient-support line (1-877-411-EGRI) before filling the first prescription.
3. Submit a PA with full clinical documentation referencing the HIV Medicine Association 2023 guidelines [10].
4. If PA is denied, file an appeal with specialist support; appeal success rates exceed 60% with documentation [11].
5. For commercially insured patients, apply for the manufacturer copay card.
6. For 340B-eligible clinics, confirm the drug is on the entity's covered-drug list through HRSA [12].
7. Use HSA/FSA funds for any remaining out-of-pocket cost, and obtain an LMN proactively [17].
8. If considering compounded tesamorelin, request a CoA and confirm the compounding pharmacy's 503A licensure with your state board of pharmacy.
9. Do not purchase tesamorelin from international or gray-market sources. The legal, safety, and therapeutic risks outweigh any apparent cost savings.

The FDA's personal-importation guidance page notes that the agency "exercises enforcement discretion" only when no U.S.-approved alternative exists, a condition Egrifta does not meet [4].